Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Healing of erosive esophagitis.
* Maintenance of healing of erosive esophagitis.
* Treatment of duodenal ulcers.
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg once daily.
* **GERD (symptomatic relief):** 20 mg orally once daily for up to 8 weeks.
* **Duodenal ulcers:** 40 mg orally once daily, may be taken with or without food.
* **Pathological hypersecretory conditions:** Starting dose is 40 mg orally or intravenously twice daily. Doses may be increased to 240 mg daily as needed.
## Pediatric Dosing
* **Erosive esophagitis (age 5 to 15 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (age 16 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* Dosing for younger pediatric patients or other indications is not well established and requires careful consideration and may necessitate consultation with a pediatric gastroenterologist or infectious disease specialist.
## Dose Adjustments
No dose adjustment is typically necessary for patients with hepatic or renal impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use may be associated with an increased risk of fractures, C. difficile infection, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Pantoprazole can decrease their absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may affect the metabolism of drugs like clopidogrel.
## Monitoring
* Monitor for signs and symptoms of C. difficile infection.
* Monitor serum magnesium levels, especially with prolonged use (typically initiated after 1 year of therapy).
* Monitor for signs of vitamin B12 deficiency with prolonged therapy.
* Assess bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Intravenous pantoprazole is generally reserved for situations where oral administration is not feasible.
* For GERD symptom relief, pantoprazole 20 mg once daily is often sufficient.
* The risk of adverse effects, particularly fractures and C. difficile infection, increases with longer duration of therapy. Consider step-down therapy or intermittent use when clinically appropriate.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete and up-to-date details before making clinical decisions.
